8.88
+2.54%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HPGC Renmintongtai Pharmaceutical
Its shares trade on Shanghai under the ticker 600829.SS. It has been listed since 24 February 1994. In the fiscal year to 31 December 2025, it reported revenue of CN¥10.38bn and net income of CN¥133.8m. At that date it held total assets of CN¥7.17bn and shareholders' equity of CN¥3.02bn.
HPGC Renmintongtai Pharmaceutical Corp. engages in the operation of pharmaceutical business. The company is headquartered in Harbin, Heilongjiang. Group Sanjing Pharmaceutical Shareholding Co., Ltd., is a China-based company, principally engaged in the wholesale and retail of pharmaceuticals. The firm principally engages in the sales of Chinese medicines and western drugs. The company also engages in the sales of medical equipment, healthcare products, daily necessities, glass apparatus, chemical, among others. The firm distributes its products mainly within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 24 Feb 1994
- Employees
- 3,030
- Website
- hyrmtt.com.cn ↗
Leadership
Pay as last reported
- Mr. Weidong ZhuChairman of the Board, General Manager, since 2016CN¥1.0m
- Ms. Ping GuanFinance Director, Deputy General Manager
- Mr. Congfeng GuDeputy General ManagerCN¥891,200
- Mr. Wei XiongDeputy General ManagerCN¥1.0m
- Mr. Lei WangSecretary of the BoardCN¥155,700
- Mr. Xiaodong MengDirector
- Mr. Cheng PengDirector
- Mr. Shiwei YinDirector
- Ms. Dan GuoIndependent Director
- Ms. Dongping HanIndependent DirectorCN¥80,000
- Mr. Bin WuIndependent DirectorCN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HPGC Renmintongtai employs 3,030 full-time employees in Harbin, China.
- Group Sanjing Pharmaceutical distributes Chinese medicines and western drugs nationwide.
- The company operates in the Health Care sector with diverse product lines including medical equipment.
Weaknesses
- The company focuses solely on domestic markets in China, limiting international expansion.
- Group Sanjing Pharmaceutical's business is restricted to wholesale and retail pharmaceuticals.
- HPGC Renmintongtai has no mention of international operations or global presence.
Opportunities
- Expanding into international markets could leverage China's growing pharmaceutical exports.
- The Health Care sector in China shows potential for increased demand for medical equipment.
- Group Sanjing Pharmaceutical can grow by adding new product lines like healthcare products.
Threats
- Domestic competition in China's pharmaceutical industry is intense.
- The Health Care sector faces regulatory challenges in China's evolving market.
- Group Sanjing Pharmaceutical may face supply chain disruptions in domestic markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.